KNUST Joins €11 Million Global Consortium to Fast-Track Dengue Vaccine Trials in sub-Saharan Africa

The School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST) has officially joined the DENSTAR Project, an international consortium dedicated to accelerating the licensure and rollout of the 'DengiAll' vaccine across sub-Saharan Africa. Launched on June 1, 2026, the four-year initiative is supported by €11 million in funding from the Global Health EDCTP3 Joint Undertaking and the European Union. This strategic partnership involves ten institutions across nine countries, aiming to combat the rising threat of dengue fever in a region where the disease is increasingly prevalent due to rapid urbanization and the effects of climate change.

The DengiAll vaccine represents a significant technological leap in the fight against the mosquito-borne virus. As a single-dose, tetravalent live-attenuated vaccine, it is designed to protect against all four serotypes of the dengue virus. Crucially, the vaccine does not require prior serological screening of recipients to determine past exposure—a major hurdle for existing vaccines. This characteristic makes it particularly suitable for large-scale deployment in low-income regions where complex medical screening is often cost-prohibitive or logistically impossible.

As a primary partner in the consortium, KNUST will host Phase III clinical trials to rigorously evaluate the vaccine's safety and efficacy among both African adults and children. These trials are essential for ensuring that the vaccine performs effectively within the specific genetic and environmental contexts of the continent. By providing high-quality clinical data, the project aims to secure regulatory approval and facilitate a smooth transition from research to public health implementation.

The broader implications of the DENSTAR Project extend beyond the immediate clinical results, offering a potential solution to a growing public health crisis in Africa. By fostering international collaboration and local capacity building, the initiative seeks to establish a sustainable framework for vaccine distribution. Success in these trials could significantly reduce the morbidity and mortality associated with dengue fever, ultimately enhancing public health outcomes and economic stability across the sub-Saharan region.